A clinical trial using foused ultrasound to enhance systemic chemotherapy of osteosarcoma

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043503

Enrollment

Unknown

Registered

2021-02-21

Start date

2021-02-20

Completion date

Unknown

Last updated

2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteosarcoma

Interventions

Combined Treatment Group (phase 1):Focused Ultrasound

Combined Treatment Group (phase 2):Focused Ultrasound

Eligibility

Sex/Gender

All

Age

3 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Patients with osteosarcoma who failed to receive standard chemotherapy; 2. Subjects with ECoG score less than 2; 3. Age: 3-45 years old; 4. Subjects whose estimated survival time is more than 3 months.

Exclusion criteria

Exclusion criteria: 1. Subjects with skin ulceration in the treatment area; 2. Subjects with severe hepatic and renal insufficiency.

Design outcomes

Primary

Measure	Time frame
Complications;Objective Response Rate (ORR);	—

Secondary

Measure	Time frame
Progression Free Survival (PFS);Overall Survival (OS);Tumor marker;	—

Countries

China

Contacts

Public ContactWenzhi Chen

State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University

chenwz@cqmu.edu.cn+86 23-68485021

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026